Pharming updates on study 1310 and shares in issueMarketwire
LEIDEN, NETHERLANDS -- (Marketwire) -- 06/15/12 -- Biotech company Pharming Group NV("Pharming" or "the Company") (NYSE Euronext: PHARM) today provides ashortupdate from its press release dated June 12, 2012.
Study 1310, the Phase III clinical study with RUCONEST that isintended tosupport the submission of a Biologics License Application (BLA) to the USFDA,continues to recruit with additional patients enrolled this week.Currently 70of the 75 patients required for the completion of Study 1310 have beentreated.
In addition, as announced in Pharming's press release dated December 23,2011;under the EUR8.4 million private bond, which has now been redeemed inshares infull, a top-up payment in shares caused by the drop in share price overthelast month has become due. Therefore 18,330,106 shares will be issuedto thebondholders under the terms and conditions of the bond.
As of today, the number of outstanding shares has increased from670,662,545 to688,992,651.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment ofunmetmedical needs. RUCONEST is a recombinant human C1 inhibitor approvedfor thetreatment of angioedema attacks in patients with HAE in all 27 EU countriesplusNorway, Iceland and Liechtenstein, and is distributed in the EU bySwedishOrphan Biovitrum (OMX: SOBI). RUCONEST is partnered withSantarus, Inc(NASDAQ: SNTS) in North America where the drug is undergoing Phase IIIclinicaldevelopment. The product is also being evaluated for follow-onindications inthe areas of transplantation and reperfusion injury. The advancedtechnologiesof the Company include innovative and validated platforms for theproduction ofprotein therapeutics, technology and processes for the purificationandformulation of these products. A feasibility study, using thevalidatedtransgenic rabbit platform, aimed at the development of recombinant FactorVIIIfor the treatment of Haemophilia A is underway with partner, Renova Life,Inc.Additional information is available on the Pharming website,www.pharming.com.To download the Pharming Group Investor Relations App, click here.
This press release contains forward looking statements that involveknown andunknown risks, uncertainties and other factors, which may cause theactualresults, performance or achievements of the Company to be materiallydifferentfrom the results, performance or achievements expressed or implied bytheseforward looking statements.
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1619872]ContactPharmingSijmen de VriesCEOT: +31 (0)71 524 7400Karl KeeganCFOT: +31 (0)71 524 7400FTI ConsultingJulia PhillipsT: +44 (0)207 269 7187John DineenT: +44 (0)207 269 7193
Source: Pharming Group N.V.